文献速递腹部CT

联合增强CT与CA19-9术前预测胰腺导管腺癌R0切除术后无病生存期

Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9.
PubMed 文献 · Eur Radiol · 2023-07-28

回顾性纳入138例R0切除的胰腺导管腺癌患者,按时间分为训练组91例和验证组47例,构建联合术前增强CT特征与CA19-9的临床影像模型预测无病生存期。模型在验证组预测效能优于术后临床病理模型和TNM模型,术前即可区分高风险与低风险患者。

要点

  • 术前增强CT示肿瘤直径>4 cm、胰外器官浸润、淋巴结转移、周边强化及CA19-9>180 U/mL为独立预后因素。
  • 临床影像模型预测无病生存期优于术后临床病理模型和TNM模型,C-index分别为0.802 vs 0.787和0.802 vs 0.711。
  • 模型术前划分的低风险患者无病生存期显著优于高风险患者(训练组P<0.001,验证组P<0.01)。

核心结论

  • 联合术前增强CT特征与血清CA19-9的临床影像模型有助于术前预测胰腺导管腺癌R0切除术后无病生存期,可能辅助临床决策。

研究设计与样本

  • 回顾性研究,共纳入138例R0切除的胰腺导管腺癌患者,按时间分为训练组91例(2014年1月至2019年7月)和验证组47例(2019年8月至2020年12月),采用单因素和多因素Cox回归构建模型。

关键影像表现/征象

  • 增强CT示肿瘤直径>4 cm为独立预后因素。
  • 增强CT示胰外器官浸润为独立预后因素。
  • 增强CT报告淋巴结转移为独立预后因素。
  • 增强CT示周边强化为独立预后因素。
  • 术前CA19-9>180 U/mL为独立预后因素。

诊断标准与关键数值

  • 临床影像模型在验证组预测无病生存期的C-index为0.802,优于术后临床病理模型的0.787(P<0.05)。
  • 临床影像模型在验证组C-index为0.802,优于TNM模型的0.711(P<0.001)。
  • 模型定义的低风险患者无病生存期显著优于高风险患者(训练组P<0.001,验证组P<0.01)。

临床应用与阅片要点

  • 作者认为该模型可能有助于术前识别复发和转移高风险患者,这些患者可能从新辅助治疗中获益。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To investigate the efficiency of a combination of preoperative contrast-enhanced computed tomography (CECT) and carbohydrate antigen 19-9 (CA19-9) in predicting disease-free survival (DFS) after R0 resection of pancreatic ductal adenocarcinoma (PDAC).

METHODS: A total of 138 PDAC patients who underwent curative R0 resection were retrospectively enrolled and allocated chronologically to training (n = 91, January 2014-July 2019) and validation cohorts (n = 47, August 2019-December 2020). Using univariable and multivariable Cox regression analyses, we constructed a preoperative clinicoradiographic model based on the combination of CECT features and serum CA19-9 concentrations, and validated it in the validation cohort. The prognostic performance was evaluated and compared with that of postoperative clinicopathological and tumor-node-metastasis (TNM) models. Kaplan-Meier analysis was conducted to verify the preoperative prognostic stratification performance of the proposed model.

RESULTS: The preoperative clinicoradiographic model included five independent prognostic factors (tumor diameter on CECT > 4 cm, extrapancreatic organ infiltration, CECT-reported lymph node metastasis, peripheral enhancement, and preoperative CA19-9 levels > 180 U/mL). It better predicted DFS than did the postoperative clinicopathological (C-index, 0.802 vs. 0.787; p < 0.05) and TNM (C-index, 0.802 vs. 0.711; p < 0.001) models in the validation cohort. Low-risk patients had significantly better DFS than patients at the high-risk, defined by the model preoperatively (p < 0.001, training cohort; p < 0.01, validation cohort).

CONCLUSIONS: The clinicoradiographic model, integrating preoperative CECT features and serum CA19-9 levels, helped preoperatively predict postsurgical DFS for PDAC and could facilitate clinical decision-making.

CLINICAL RELEVANCE STATEMENT: We constructed a simple model integrating clinical and radiological features for the prediction of disease-free survival after curative R0 resection in patients with pancreatic ductal adenocarcinoma; this novel model may facilitate preoperative identification of patients at high risk of recurrence and metastasis that may benefit from neoadjuvant treatments.

KEY POINTS: • Existing clinicopathological predictors for prognosis in pancreatic ductal adenocarcinoma (PDAC) patients who underwent R0 resection can only be ascertained postoperatively and do not allow preoperative prediction. • We constructed a clinicoradiographic model, using preoperative contrast-enhanced computed tomography (CECT) features and preoperative carbohydrate antigen 19-9 (CA19-9) levels, and presented it as a nomogram. • The presented model can predict disease-free survival (DFS) in patients with PDAC better than can postoperative clinicopathological or tumor-node-metastasis (TNM) models.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Li D, Peng Q, Wang L, et al. Preoperative prediction of disease-free survival in pancreatic ductal adenocarcinoma patients after R0 resection using contrast-enhanced CT and CA19-9. Eur Radiol. 2023. PMID: 37507611. doi:10.1007/s00330-023-09980-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。